

MEDICAL PRESCRIPTION FORM



Laboratoire Cerba Customer relationship service Tél.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

Two-sided Document

HEMATO-ONCOLOGY

MOLECULAR GENETICS

SAMPLING	
EDTA whole blood (2x5 ml) EDTA Bone Marrow (1 to 2 ml) Lymph node Other, specify: Sampling date LILI IIII Sampling time III h III min	Customer: C
PATIENT	PRESCRIBER
LAST NAME FIRST NAME Birth name. Adress City Country Date of birth J Sex	LAST NAME
REQUESTED TEST	
CHRONIC MYELOID LEUKEMIA (CML) Diagnostic workup : Detection of common BCR-ABL1 transcript fusions (p210, p190) Follow up monitoring / quantification : (BCR-ABL1 fusion type to be quantified must be precised in the absence of previous Cerba quantification) Type of transcript fusion: p210 M-BCR-ABL1 p190 m-BCR-ABL1 Treatment discontinuation NO YES Not specified	MYELOPROLIFERATIVE NEOPLASMS BCR-ABL1 NEGATIVE MPN diagnostic package : JAK2 V617F and exon12 / CALR / MPL Isolated mutation screening (Extracted DNA retained for possible further addition if required): JAK2 V617F (first intention diagnostic test) JAK2 exon 12 mutation CALR MPL FIP1L1-PDGFRA transcript fusion Please Note: The isolated search for c-kit gene mutations is no longer performed but is now included in MPN NGS panel (see below)
ACUTE MYELOID LEUKEMIA: AML	
Diagnosis: Molecular AML panel : FLT3 (ITD/TKD), NPM1, CEBPA, IDH1, IDH2 Isolated mutation screening : Detection of gene fusion : FLT3 (ITD/TKD) AML1-ETO (RUNX1-RUNX1T1) / IDH1 t(8;21) IDH2 CBFβ-MYH11/inv(16) TP53 PML-RARA/t(15;17)	Minimal residual disease monitoring: AML1-ETO (RUNX1-RUNX1T1) CBFβ-MYH11 types A / D / E PML-RARA type bcr 1 bcr 2 bcr 3
ACUTE LYMPHOBLASTIC LEUKEMIA: ALL	
Diagnostic workup :	Follow up monitoring / quantification : p210 M-BCR-ABL1 transcript fusions quantification p190 m-BCR-ABL1 transcript fusions quantification

Cerba Laboratory is responsible for processing your personal data provided in this form as the data controller, in order to perform tests, interpret them, transmit results, and manage the laboratory's administrative tasks. If you are a patient, your data may then be reused for anonymization purposes for scientific research, quality control, statistical studies, or satisfaction surveys. To learn more about how your personal data is processed, your rights, and research projects' tasks. To exercise your rights of opsoition, contact our Dela Protection Officer (DPO) at: right cerba@laboreta.com / CERBA_RPD – 2AC DES EPINEAUX 10-12 Avenue ROLAND MORENO CS 51312 95740 FREPILLON. / If you are a patient, in accordance with applicable regulations, once your tests are completed, any remaining samples from your tests will be disposed of. However, they may be kept for use in scientific research or quality control purposes, either directly or after transfer to third parties, in strict compliance with medical confidentiality. You may object to such use by simply making a request to our DPO (contact details above).



MEDICAL PRESCRIPTION FORM

Two-sided Document



Laboratoire Cerba Customer relationship service Tél.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29 Email : intgb@lab-cerba.com

HEMATO-ONCOLOGY

MOLECULAR GENETICS

LYMPHOID NEOPLASMS

- Determination of IGHV gene SHM status CLL Other lymphoma Please join the result of lymhocyte immunophenotyping
- Cyclin D1 overexpression
- TP53 mutations

MYD88 L265P Please Note: The joint search for MYD88 and CXCR4 mutations can be performed during the lymphoid NGS panel (see below)

B-cell clonality (Immunoglobulin Gene rearrangement)

T-Cell clonality (TCR rearrangement)

BRAF V600E mutation

TARGETED NGS PANELS FOR HEMATOLOGIC MALIGNANCIES

Myeloproliferative Neoplasm, 24 genes panel

ASXL1, CALR, CBL, CSF3R, DNMT3A, EZH2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2

Myelodysplastic Neoplasm, 31 genes panel

ASXL1, BCOR, BCORL1, CBL, CEBPA, DNMT3A, ETNK1, ETV6, EZH2, FLT3, GATA2, GNB1, IDH1, IDH2, KMT2A, KRAS, NF1, NPM1, NRAS, PHF6, PPM1D, PRPF8, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TP53, U2AF1, WT1

Acute Myeloid Leukemia, 21 genes panel

ASXL1, BCOR, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, KIT, KMT2A, NPM1, PHF6, RUNX1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2

Pan-Myeloid AML / MDS / CMML / MPN, 50 genes panel

ASXL1, ANKRD26, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, CSNK1A1, DNMT3A, DDX41, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, GNAS, GNB1, IDH1, IDH2, JAK2, KDM6A, KIT, KMT2A, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PRPF8, PTEN, PTPN11, RAD21, RUNX1, SAMD9, SETBP1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, UBA1, U2AF1, WT1, ZRSR2

Lymphoid neoplasm including TP53, 18 genes panel

BIRC3, BRAF, BTK, CXCR4, DNMT3A, IDH2, MYD88, NOTCH1, NOTCH2, PLCG2, PTEN, RHOA, SF3B1, STAT3, STAT5B, TET2, TP53, XPO1

Plasma Cell Myeloma, 26 genes panel

BIRC3, BRAF, CCND1, CDKN2A, CRBN, CUL4A, CUL4B, CXCR4, DIS3, EGFR, IDH1, IDH2, IKZF1, IKZF3, KRAS, MYC, MYD88, NRAS, NSD2, PIK3CA, PIM1, STAT3, TENT5C, TP53, TRAF3, XBP1

OTHER REQUEST RNA extraction for conservation DNA extraction for conservation Other, please specify: